EGFR Clinical Trials

87 recruitingLast updated: June 17, 2026

There are 87 actively recruiting egfr clinical trials across 31 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1. Top locations include Shanghai, Shanghai Municipality, China, Guangzhou, Guangdong, China, Fairfax, Virginia, United States. Updated daily from ClinicalTrials.gov.


EGFR Trials at a Glance

87 actively recruiting trials for egfr are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 2 with 41 trials, with the heaviest enrollment activity in Shanghai, Guangzhou, and Fairfax. Lead sponsors running egfr studies include Sun Yat-sen University, Tianjin Medical University Cancer Institute and Hospital, and Instituto Nacional de Cancerologia de Mexico.

Treatments under study

About EGFR Clinical Trials

Looking for clinical trials for EGFR? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new EGFR trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about EGFR clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 87 trials

Recruiting
Phase 1Phase 2

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

HER2 MutationAdvanced Non-Small Cell Lung CancerEGFR Mutation
Bayer400 enrolled94 locationsNCT05099172
Recruiting
Phase 1Phase 2

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Metastatic Solid TumorLocally Advanced Solid TumorEGFR Overexpression
Yuhan Corporation80 enrolled4 locationsNCT06975410
Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting
Phase 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled74 locationsNCT07185997
Recruiting
Phase 2

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

EGFR Activating MutationLung Cancer Non-Small Cell Cancer (NSCLC)PD-1 Antibody
Nanfang Hospital, Southern Medical University32 enrolled1 locationNCT07637448
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

Brain TumorBrain CancerGlioblastoma+4 more
Northwell Health33 enrolled1 locationNCT02861898
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1Phase 2

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech42 enrolled1 locationNCT07617805
Recruiting
Not Applicable

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)Antineoplastic Agents, ImmunologicalVEGFR-TKI
Federation Francophone de Cancerologie Digestive300 enrolled83 locationsNCT07124858
Recruiting
Phase 1Phase 2

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Non-small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament345 enrolled24 locationsNCT06043817
Recruiting
Phase 1

Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

EGFR Mutation-positive NSCLC
AstraZeneca12 enrolled3 locationsNCT07500987
Recruiting
Phase 1

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

NeuroblastomaNasopharyngeal CarcinomaRhabdomyosarcoma+7 more
Sun Yat-sen University51 enrolled1 locationNCT07584499
Recruiting

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNSCLC+6 more
GFPC Investigation100 enrolled16 locationsNCT07563205
Recruiting
Not Applicable

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Groupe Francais De Pneumo-Cancerologie30 enrolled18 locationsNCT06247826
Recruiting
Phase 1

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Solid TumorsNSCLCEGFR Exon 20 Insertion Mutations+1 more
ORIC Pharmaceuticals76 enrolled4 locationsNCT06816992
Recruiting
Phase 2

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT07548060
Recruiting

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

EGFR-mutated NSCLC
Gruppo Oncologico Italiano di Ricerca Clinica100 enrolled25 locationsNCT07363252
Recruiting
Phase 1

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumor MalignanciesEGFREGFR Positive Solid Tumors
Vir Biotechnology, Inc.450 enrolled4 locationsNCT06960395
Recruiting
Phase 2

Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

NSCLC (Advanced Non-small Cell Lung Cancer)EGFRMyelosuppression
The First Affiliated Hospital of Xiamen University49 enrolled1 locationNCT06992739